Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US-2022347228-A1 · Nov 3, 2022 · US
Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US12508284B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12508284-B2 |
| Application number | US-202117557246-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 21, 2021 |
| Priority date | Mar 15, 2013 |
| Publication date | Dec 30, 2025 |
| Grant date | Dec 30, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor progenitor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor progenitor cells.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A preparation comprising: a plurality of cells, wherein at least 85% of the cells are CHX10 (−) photoreceptor progenitor cells that express one or more of the markers Nr2e3, Trβ2, Mash1, RORβ and NRO, and wherein the cells are differentiated in vitro from pluripotent stem cells; and a medium suitable for maintaining the viability of the cells, wherein the CHX10 (−) photoreceptor progenitor cells that express one or more of the markers Nr2e3, Trβ2, Mash1, RORβ and/or NRO: secrete one or more neuroprotective factors; have phagocytic activity; or a combination thereof. 2 . The preparation of claim 1 , wherein at least 85% of the cells are CHX10 (−) when assessed by immunostaining. 3 . The preparation of claim 1 , wherein at least 90% of the cells are CHX10 (−) by immunostaining. 4 . The preparation of claim 1 , wherein at least 95% of the cells are CHX10 (−) by immunostaining. 5 . The preparation of claim 1 , wherein the CHX10 (−) photoreceptor progenitor cells that express one or more of the markers Nr2e3, Trβ2, Mash1, RORβ and NRO secrete one or more neuroprotective factors. 6 . The preparation of claim 1 , wherein the CHX10 (−) cells that express one or more of the markers Nr2e3, Trβ2, Mash1, RORβ and NRO have phagocytic activity. 7 . The preparation of claim 1 , wherein the CHX10 (−) cells that express one or more of the markers Nr2e3, Trβ2, Mash1, RORβ and NRO: secrete one or more neuroprotective factors; and have phagocytic activity. 8 . The preparation of claim 1 , wherein the CHX10 (−) cells that express one or more of the markers Nr2e3, Trβ2, Mash1, RORβ and/or NRO have the ability to phagocytose isolated photoreceptor outer segments, fluorescent bioparticles, or both photoreceptor outer segments and fluorescent bioparticles. 9 . The preparation of claim 1 , wherein the CHX10 (−) cells that express one or more of the markers Nr2e3, Trβ2, Mash1, RORβ and NRO are unable to differentiate into cone photoreceptor cells. 10 . The preparation of claim 1 , wherein the preparation is a pharmaceutical preparation, and wherein the pharmaceutical preparation comprises a pharmaceutically acceptable carrier. 11 . The preparation of claim 1 , wherein the preparation is a cryopreserved preparation, and wherein the cryopreserved preparation comprises a cryopreservative compatible with the viability of the cells. 12 . The preparation of claim 1 , wherein the cells of the preparation are suspended in the medium suitable for maintaining the viability of the cells. 13 . The preparation of claim 1 , further comprises a matrix or a support, wherein the cells of the preparation are attached to the matrix or the support. 14 . The preparation of claim 1 , wherein less than 1% of the cells of the preparation are human embryonic stem cells, induced pluripotent stem cells, eye field progenitor cells, retinal ganglion cells, mature photoreceptors, and/or amacrine cells. 15 . The preparation of claim 1 , wherein the pluripotent stem cells are ES cells. 16 . The preparation of claim 1 , wherein the pluripotent stem cells are iPS cells. 17 . The preparation of claim 1 , wherein the cells are human cells. 18 . The preparation of claim 1 , wherein the cells of the preparation are HLA-matched or genetically identical relative to each other.
Assignees
Inventors
Classifications
from embryonic cells · CPC title
Small molecules not provided for elsewhere · CPC title
Proteins not provided for elsewhere · CPC title
Kinases (EC 2.7.) · CPC title
Sexual steroids · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12508284B2 cover?
- Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor progenitor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor progenitor cells.
- Who is the assignee on this patent?
- Astellas Inst For Regenerative Medicine
- What technology area does this patent fall under?
- Primary CPC classification A61K35/30. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).